Introduction
Methods
Study design and patient selection
Selection and management of LuTx patients
Definition of relevant CAD
Clinical endpoints
Risk factor analysis
Ethics approval
Statistical analysis
Results
Study population
Baseline characteristics of unmatched LuTx patients without and with relevant CAD | ||||
---|---|---|---|---|
Characteristics | Overall (n = 1003) | Patients without CAD (n = 899) | Patients with CAD (n = 104) | p-value |
Demographics | ||||
Age [years], median [IQR] | 54.73 [45.78, 60.53] | 53.96 [44.45, 59.85] | 60.28 [56.71, 63.24] | < 0.001 |
Sex [male], n (%) | 547 (54.5) | 470 (52.3) | 77 (74.0) | < 0.001 |
Body mass index [kg/m2], median [IQR] | 22.39 [19.52, 25.90] | 22.22 [19.37, 25.62] | 24.13 [21.25, 27.41] | < 0.001 |
Diagnosis | ||||
Restrictive lung disease, n (%) | 502 (50.0) | 428 (47.6) | 74 ( 71.2) | < 0.001 |
Obstructive lung disease, n (%) | 289 (28.8) | 259 (28.8) | 30 ( 28.8) | > 0.999 |
Vascular lung disease, n (%) | 40 (4.0) | 40 ( 4.4) | 0 ( 0.0) | 0.017 |
Cystic fibrosis, n (%) | 139 (13.9) | 139 (15.5) | 0 ( 0.0) | < 0.001 |
Other, n (%) | 33 (3.3) | 33 ( 3.7) | 0 ( 0.0) | 0.041 |
Cardiovascular risk factors | ||||
Hypertension, n (%) | 359 (35.8) | 289 (32.1) | 70 ( 67.3) | < 0.001 |
Diabetes, n (%) | 227 (22.6) | 207 (23.0) | 20 ( 19.2) | 0.458 |
Smoking, n (%) | 438 (43.7) | 368 (40.9) | 70 ( 67.3) | < 0.001 |
Cholesterol [mg/dl], median [IQR] | 159.00 [124.25, 204.00] | 160.00 [124.00, 205.75] | 147.00 [126.50, 184.00] | 0.146 |
Morbidity at admission | ||||
Prior Myocardial infarction, n (%) | 19 ( 1.9) | 0 ( 0.0) | 19 ( 18.3) | < 0.001 |
Prior CABG, n (%) | 4 ( 0.4) | 0 ( 0.0) | 4 ( 3.8) | < 0.001 |
Prior PCI, n (%) | 60 ( 6.0) | 0 ( 0.0) | 60 ( 57.7) | < 0.001 |
Prior Stroke, n (%) | 19 ( 1.9) | 17 ( 1.9) | 2 ( 1.9) | > 0.999 |
Prior Pulmonary embolism, n (%) | 67 ( 6.7) | 58 ( 6.5) | 9 ( 8.7) | 0.405 |
Prior Thrombosis, n (%) | 43 ( 4.3) | 36 ( 4.0) | 7 ( 6.7) | 0.200 |
Prior PVD | 15 ( 1.5) | 9 ( 1.0) | 6 ( 5.8) | 0.003 |
Prior Atrial fibrillation, n (%) | 43 ( 4.3) | 38 ( 4.2) | 5 ( 4.8) | 0.800 |
LTOT, n (%) | 996 (99.3) | 895 (99.6) | 101 ( 97.1) | 0.028 |
CAD Characteristics | ||||
Coronary sclerosis, n (%) | 230 (22.9) | 126 ( 14.0) | 104 (100.0) | < 0.001 |
1-Vessel-Disease, n (%) | 64 ( 6.4) | 0 ( 0.0) | 64 ( 61.5) | |
2- Vessel-Disease, n (%) | 23 ( 2.3) | 0 ( 0.0) | 23 ( 22.1) | |
3- Vessel-Disease, n (%) | 17 ( 1.7) | 0 ( 0.0) | 17 ( 16.3) | |
Stenosis > 50% LM, n (%) | 2 ( 0.2) | 0 ( 0.0) | 2 ( 1.9) | |
Stenosis > 50% LAD, n (%) | 51 ( 5.1) | 0 ( 0.0) | 51 ( 49.0) | |
Stenosis > 50% LCX, n (%) | 24 ( 2.4) | 0 ( 0.0) | 24 ( 23.1) | |
Stenosis > 50% RCA, n (%) | 28 ( 2.8) | 0 ( 0.0) | 28 ( 26.9) | |
Prior PCI LM, n (%) | 6 ( 0.6) | 0 ( 0.0) | 6 ( 5.8) | |
Prior PCI LAD, n (%) | 30 ( 3.0) | 0 ( 0.0) | 30 (28.8) | |
Prior PCI LCX, n (%) | 15 ( 1.5) | 0 ( 0.0) | 15 (14.4) | |
Prior PCI RCA, n (%) | 23 ( 2.3) | 0 ( 0.0) | 23 (22.1) | |
Prior CABG, n (%) | 4 ( 0.4) | 0 ( 0.0) | 4 ( 3.8) | |
CTO, n (%) | 4 ( 0.4) | 0 ( 0.0) | 4 ( 3.8) | |
Hemodynamics | ||||
Cardiac Index [L/m2], median [IQR] | 3.10 [2.60, 3.60] | 3.10 [2.68, 3.70] | 2.95 [2.50, 3.40] | 0.012 |
mPAP [mmHg], median [IQR] | 25.00 [20.00, 32.00] | 25.00 [20.00, 33.00] | 24.00 [19.75, 29.00] | 0.046 |
PCWP [mmHg], median [IQR] | 9.00 [6.00, 11.00] | 9.00 [6.00, 11.00] | 8.00 [5.00, 11.00] | 0.174 |
PVR [WE], median [IQR] | 2.80 [2.00, 4.43] | 2.83 [2.00, 4.50] | 2.70 [2.00, 4.01] | 0.413 |
Functional tests | ||||
6MWD [m], median [IQR] | 220.00 [100.00, 320.00] | 220.00 [100.00, 320.00] | 183.00 [90.00, 320.00] | 0.357 |
FVC [% of reference], median [IQR] | 40.40 [32.00, 53.00] | 40.00 [31.00, 52.70] | 43.00 [35.00, 54.70] | 0.074 |
FEV1 [% of reference], median [IQR] | 31.00 [21.00, 47.00] | 30.00 [20.55, 46.00] | 44.00 [23.00, 56.25] | < 0.001 |
LVEF | ||||
> 55 [%], n (%) | 933 (93.0) | 842 (93.7) | 91 ( 87.5) | 0.027 |
45 – 55 [%], n (%) | 48 ( 4.8) | 39 ( 4.3) | 9 ( 8.7) | 0.083 |
35 – 45 [%], n (%) | 13 ( 1.3) | 10 ( 1.1) | 3 ( 2.9) | 0.144 |
TAPSE | ||||
> 16 [mm], n (%) | 909 (90.6) | 816 (90.8) | 93 ( 89.4) | 0.682 |
< 16 [mm], n (%) | 69 ( 6.9) | 61 ( 6.8) | 8 ( 7.7) | 0.682 |
Valve Disease | ||||
No valve disease > II°, n (%) | 855 (85.2) | 767 (85.3) | 88 ( 84.6) | 0.881 |
Aortic valve stenosis > II°, n (%) | 3 ( 0.3) | 2 ( 0.2) | 1 ( 1.0) | 0.280 |
Aortic valve regurgitation > II°, n (%) | 5 ( 0.5) | 4 ( 0.4) | 1 ( 1.0) | 0.422 |
Mitral valve regurgitation > II°, n (%) | 7 ( 0.7) | 6 ( 0.7) | 1 ( 1.0) | 0.536 |
Tricuspid valve regurgitation > II°, n (%) | 121 (12.1) | 110 (12.2) | 11 ( 10.6) | 0.751 |
Duplex of the A. carotis | ||||
No plaques, n (%) | 884 (88.9) | 805 (90.4) | 79 ( 76.0) | < 0.001 |
Plaques < 50%, n (%) | 97 ( 9.8) | 76 ( 8.5) | 21 ( 20.2) | < 0.001 |
Stenosis > 50%, n (%) | 13 ( 1.3) | 9 ( 1.0) | 4 ( 3.8) | 0.038 |
Lab results | ||||
Creatinine [mg/dl], median [IQR] | 0.80 [0.70, 1.00] | 0.80 [0.70, 1.00] | 0.90 [0.80, 1.00] | 0.003 |
Bilirubin [mg/dl], median [IQR] | 0.50 [0.30, 0.70] | 0.50 [0.30, 0.70] | 0.50 [0.30, 0.70] | 0.528 |
Blood Group | ||||
A, n (%) | 438 (43.7) | 392 (43.6) | 46 ( 44.2) | 0.917 |
B, n (%) | 161 (16.1) | 142 (15.8) | 19 ( 18.3) | 0.484 |
AB, n (%) | 52 ( 5.2) | 51 ( 5.7) | 1 ( 1.0) | 0.035 |
0, n (%) | 352 (35.1) | 314 (34.9) | 38 ( 36.5) | 0.746 |
Procedural characteristics | ||||
ECMO bridge to transplant, n (%) | 67 ( 6.7) | 63 ( 7.0) | 4 ( 3.8) | 0.299 |
Double lung transplantation, n (%) | 732 (73.0) | 684 (76.1) | 48 ( 46.2) | < 0.001 |
Reoperation within hospital stay, n (%) | 272 (27.1) | 255 (28.4) | 17 ( 16.3) | 0.010 |
Baseline characteristics of matched patients without and with relevant CAD | ||||
---|---|---|---|---|
Characteristics | Patients without CAD (n = 98) | Patients with CAD (n = 98) | p-value | Absolute SMD |
Demographics | ||||
Age [years], median [IQR] | 60.00 [57.00, 63.00] | 60.00 [56.00, 63.00] | 0.077 | |
Sex [male], n (%) | 73 (74.5) | 71 (72.4) | 0.047 | |
Body mass index [kg/m2], median [IQR] | 23.63[20.61, 27.44] | 24.08 [21.22, 27.62] | 0.065 | |
Diagnosis | ||||
Restrictive lung disease, n (%) | 61 (62.2) | 69 (70.4) | 0.290 | |
Obstructive lung disease, n (%) | 35 (35.7) | 29 (29.6) | 0.446 | |
Vascular lung disease, n (%) | 1 (1.0) | 0 (0.0) | > 0.999 | |
Cystic fibrosis, n (%) | 0 (0.0) | 0 (0.0) | - | |
Other, n (%) | 1 (1.0) | 0 (0.0) | > 0.999 | |
Cardiovascular risk factors | ||||
Hypertension, n (%) | 59 (60.2) | 65 (66.3) | 0.131 | |
Diabetes, n (%) | 18 (18.4) | 19 (19.4) | 0.026 | |
Smoking, n (%) | 70 (71.4) | 65 (66.3) | 0.109 | |
Cholesterol [mg/dl], median [IQR] | 153.00 [125.50, 195.00] | 145.00 [125.00, 182.25] | 0.333 | |
Morbidity at admission | ||||
Prior Myocardial infarction, n (%) | 0 (0.0) | 17 (17.3) | < 0.001 | |
Prior CABG, n (%) | 0 (0.0) | 3 (3.1) | 0.246 | |
Prior PCI, n (%) | 0 (0.0) | 55 (56.1) | < 0.001 | |
Prior Stroke, n (%) | 3 (3.1) | 2 (2.0) | > 0.999 | |
Prior Pulmonary embolism, n (%) | 3 (3.1) | 8 (8.2) | 0.213 | |
Prior Thrombosis, n (%) | 2 (2.0) | 7 (7.1) | 0.170 | |
Prior PVD | 2 (2.0) | 5 (5.1) | 0.445 | |
Prior Atrial fibrillation, n (%) | 7 (7.1) | 5 (5.1) | 0.767 | |
LTOT, n (%) | 98 (100.0) | 95 (96.9) | 0.246 | |
CAD Characteristics | ||||
Coronary sclerosis, n (%) | 27 (27.6) | 98 (100.0) | < 0.001 | |
1-Vessel-Disease, n (%) | 0 (0.0) | 62 (63.3) | ||
2- Vessel-Disease, n (%) | 0 (0.0) | 21 (21.4) | ||
3- Vessel-Disease, n (%) | 0 (0.0) | 15 (15.3) | ||
Stenosis > 50% LM, n (%) | 0 (0.0) | 2 (2.0) | ||
Stenosis > 50% LAD, n (%) | 0 (0.0) | 48 (49.0) | ||
Stenosis > 50% LCX, n (%) | 0 (0.0) | 22 (22.4) | ||
Stenosis > 50% RCA, n (%) | 0 (0.0) | 25 (25.5) | ||
Prior PCI LM, n (%) | 0 (0.0) | 6 (6.1) | ||
Prior PCI LAD, n (%) | 0 (0.0) | 27 (27.6) | ||
Prior PCI LCX, n (%) | 0 (0.0) | 15 (15.3) | ||
Prior PCI RCA, n (%) | 0 (0.0) | 19 (19.4) | ||
Prior CABG, n (%) | 0 (0.0) | 3 (3.1) | ||
CTO, n (%) | 0 (0.0) | 4 (4.1) | ||
Hemodynamics | ||||
Cardiac Index [L/m2], median [IQR] | 3.00 [2.62, 3.40] | 3.00 [2.52, 3.40] | 0.095 | |
mPAP [mmHg], median [IQR] | 24.00 [19.00, 30.00] | 24.00 [20.00, 29.00] | 0.148 | |
PCWP [mmHg], median [IQR] | 8.00 [6.00, 11.00] | 8.00 [5.00, 11.00] | 0.011 | |
PVR [WE], median [IQR] | 2.70 [1.85, 3.85] | 2.80 [2.00, 4.06] | 0.562 | |
Functional tests | ||||
6MWD [m], median [IQR] | 240.00 [120.00, 317.50] | 181.50 [87.50, 312.50] | 0.161 | |
FVC [% of reference], median [IQR] | 43.00 [35.00, 56.00] | 43.00 [35.00, 54.45] | 0.066 | |
in obstructive lung disease, median [IQR] | 45.00 [35.50, 53.50] | 39.00 [33.00, 51.00] | ||
in restrictive lung disease, median [IQR] | 39.85 [32.00, 56.00] | 43.00 [35.00, 54.00] | ||
FEV1 [% of reference], median [IQR] | 40.00 [22.10, 58.50] | 42.00 [23.00, 56.00] | 0.077 | |
in obstructive lung disease, median [IQR] | 21.00 [19.00, 25.75] | 21.00 [20.00, 23.00] | ||
in restrictive lung disease, median [IQR] | 47.50 [36.75, 63.25] | 50.00 [40.00, 59.00] | ||
LVEF | ||||
> 55 [%], n (%) | 90 (91.8) | 85 (86.7) | 0.126 | |
45 – 55 [%], n (%) | 5 (5.1) | 9 (9.2) | 0.406 | |
35 – 45 [%], n (%) | 0 (0.0) | 3 (3.1) | 0.246 | |
TAPSE | ||||
> 16 [mm], n (%) | 87 (88.8) | 88 (89.8) | > 0.999 | |
< 16 [mm], n (%) | 7 (7.1) | 7 (7.1) | > 0.999 | |
Valve Disease | ||||
No valve disease > II°, n (%) | 82 (83.7) | 83 (84.7) | > 0.999 | |
Aortic valve stenosis > II°, n (%) | 0 (0.0) | 1 (1.0) | > 0.999 | |
Aortic valve regurgitation > II°, n (%) | 1 (1.0) | 1 (1.0) | > 0.999 | |
Mitral valve regurgitation > II°, n (%) | 0 (0.0) | 1 (1.0) | > 0.999 | |
Tricuspid valve regurgitation > II°, n (%) | 11 (11.2) | 11 (11.2) | > 0.999 | |
Duplex of the A. carotis | ||||
No plaques, n (%) | 83 (84.7) | 76 (77.6) | 0.135 | |
Plaques < 50%, n (%) | 11 (11.2) | 18 (18.4) | 0.227 | |
Stenosis > 50%, n (%) | 2 (2.0) | 4 (4.1) | 0.683 | |
Lab results | ||||
Creatinine [mg/dl], median [IQR] | 0.90 [0.80, 1.08] | 0.90 [0.80, 1.00] | 0.860 | |
Bilirubin [mg/dl], median [IQR] | 0.50 [0.30, 0.70] | 0.50 [0.32, 0.70] | 0.403 | |
Blood Group | ||||
A, n (%) | 46 (46.9) | 43 (43.9) | 0.774 | |
B, n (%) | 16 (16.3) | 18 (18.4) | 0.851 | |
AB, n (%) | 6 (6.1) | 1 (1.0) | 0.118 | |
0, n (%) | 30 (30.6) | 36 (36.7) | 0.450 | |
Procedural characteristics | ||||
ECMO bridge to transplant, n (%) | 3 (3.1) | 4 (4.1) | 0.053 | |
Double lung transplantation, n (%) | 46 (46.9) | 48 (49.0) | 0.041 | |
Reoperation within hospital stay, n (%) | 16 (16.3) | 16 (16.3) | > 0.999 |
Differences in baseline characteristics between patients without and with relevant CAD
Survival
In-hospital mortality in matched patients without and with relevant CAD | |||
---|---|---|---|
Characteristics | Patients without CAD (n = 98) | Patients with CAD (n = 98) | p-value |
Survival | |||
In-hospital mortality | 8 (8.2) | 8 (8.2) | > 0.999 |
Cardiovascular events following LuTx
Adverse events in matched patients without and with relevant CAD | |||
---|---|---|---|
Characteristics | Patients without CAD (n = 98) | Patients with CAD (n = 98) | p-value |
Adverse Events post transplantation | |||
Myocardial Infarction, n (%) | 2 (2.0) | 7 (7.1) | 0.170 |
Coronary angiography, n (%) | 5 (5.1) | 17 (17.3) | 0.011 |
PCI, n (%) | 1 (1.0) | 5 (5.1) | 0.212 |
CABG, n (%) | 0 (0.0) | 1 (1.0) | > 0.999 |
Stroke, n (%) | 6 (6.1) | 2 (2.0) | 0.279 |
Pulmonary embolism, n (%) | 11 (11.2) | 14 (14.3) | 0.669 |
Thrombosis, n (%) | 18 (18.4) | 16 (16.3) | 0.851 |
Cardiac arrest, n (%) | 11 (11.2) | 6 (6.1) | 0.310 |
Atrial fibrillation (new onset), n (%) | 23 (23.5) | 15 (15.3) | 0.206 |
Dialysis, n (%) | 11 (11.2) | 8 (8.2) | 0.630 |
Re-Operation, n (%) | 16 (16.3) | 16 (16.3) | > 0.999 |
Cause of death following LuTx
Cause of Death in matched patients without and with relevant CAD | |||
---|---|---|---|
Characteristics | Patients without CAD (n = 98) | Patients with CAD (n = 98) | p-value |
Cause of Death | |||
Bleeding, n (%) | 6 (6.1) | 2 (2.0) | 0.279 |
Chronic lung allograft dysfunction, n (%) | 6 (6.1) | 11 (11.2) | 0.118 |
Cardiovascular, n (%) | 2 (2.0) | 7 (7.1) | 0.078 |
Infection/Sepsis, n (%) | 16 (16.3) | 15 (15.3) | 0.832 |
Malignancy, n (%) | 4 (4.1) | 4 (4.1) | > 0.999 |
Multi-organ failure, n (%) | 7 (7.1) | 4 (4.1) | 0.537 |
Mors in tabula, n (%) | 1 (1.0) | 1 (1.0) | > 0.999 |
Other, n (%) | 2 (2.0) | 2 (2.0) | > 0.999 |
Unknown, n (%) | 11 (11.2) | 2 (2.0) | 0.018 |
Risk factors for in-hospital mortality in LuTx patients
(A) Risk factors for in-hospital mortality | ||||
---|---|---|---|---|
Attribute | Univariate analysis | Multivariate analysis | ||
OR [95% CI] | p-value | OR [95% CI] | p-value | |
Age at Tx [years] | 0.99 [0.98, 1.01] | 0.570 | 1.04 [1.01, 1.07] | 0.009 |
Sex [male] | 1.18 [0.76, 1.83] | 0.457 | 1.15 [0.70, 1.89] | 0.582 |
Hypertension [yes] | 1.02 [0.65, 1.60] | 0.922 | 1.13 [0.68, 1.89] | 0.640 |
Diabetes [yes] | 0.96 [0.57, 1.61] | 0.876 | 0.98 [0.53, 1.79] | 0.937 |
Smoking [yes] | 0.71 [0.46, 1.11] | 0.137 | 0.82 [0.45, 1.50] | 0.519 |
Body mass index [kg/\({{\text{m}}}^{2}\)] | 0.99 [0.94, 1.04] | 0.613 | 0.96 [0.90, 1.03] | 0.277 |
Kreatinin [mg/dl] | 1.36 [0.69, 2.69] | 0.378 | 1.08 [0.48, 2.42] | 0.855 |
Bilirubin [mg/dl] | 2.21 [1.49, 3.29] | < 0.001 | 1.90 [1.19, 3.03] | 0.007 |
Restrictive lung disease [yes] | 0.80 [0.52, 1.24] | 0.319 | 0.47 [0.21, 1.05] | 0.066 |
Obstructive lung disease [yes] | 0.87 [0.54, 1.43] | 0.590 | 0.78 [0.31, 2.01] | 0.612 |
FEV1 [% of reference] | 1.00 [0.99, 1.01] | 0.902 | 1.00 [0.98, 1.03] | 0.667 |
FVC [% of reference] | 0.99 [0.98, 1.01] | 0.269 | 0.97 [0.95, 0.99] | 0.004 |
Relevant CAD [yes] | 0.82 [0.38, 1.75] | 0.605 | 1.30 [0.55, 3.09] | 0.547 |
LVEF [abnormal] | 3.34 [1.17, 4.68] | 0.016 | 1.94 [0.87, 4.33] | 0.106 |
TAPSE [reduced] | 2.81 [1.50, 5.30] | 0.001 | 1.95 [0.86, 4.41] | 0.108 |
TI [\(>\) °II] | 3.08 [1.29, 7.38] | 0.011 | 1.93 [0.64, 5.82] | 0.245 |
mPAP [mmHg] | 1.03 [1.01, 1.04] | 0.001 | 1.02 [0.99, 1.04] | 0.179 |
PCWP [mmHg] | 1.05 [1.00, 1.10] | 0.046 | 1.03 [0.98, 1.09] | 0.287 |
Double Lung Transplant [yes] | 1.82 [1.04, 3.18] | 0.036 | 2.04 [1.04, 4.01] | 0.039 |
Reoperation [yes] | 3.26 [2.10, 5.06] | < 0.001 | 2.99 [1.84, 4.87] | < 0.001 |
ECMO [yes] | 1.85 [0.91, 3.77] | 0.089 | 1.40 [0.56, 3.53] | 0.475 |
Time since first transplantation at all in the study [years] | 0.96 [0.93, 1.00] | 0.036 | 0.93 [0.89, 0.97] | 0.001 |
(B) Risk factors for all-cause mortality | ||||
Attribute | Univariate analysis | Multivariate analysis | ||
HR [95% CI] | p-value | HR [95% CI] | p-value | |
Age at Tx [years] | 1.03 [1.02, 1.04] | < 0.001 | 1.02 [1.01, 1.04] | < 0.001 |
Sex [male] | 1.27 [1.06, 1.52] | 0.009 | 1.13 [0.95, 1.34] | 0.159 |
Hypertension [yes] | 1.25 [1.05, 1.50] | 0.015 | 0.98 [0.83, 1.16] | 0.831 |
Diabetes [yes] | 0.93 [0.75, 1.15] | 0.475 | 1.15 [0.94, 1.40] | 0.178 |
Smoking [yes] | 1.26 [1.06, 1.51] | 0.011 | 0.88 [0.71, 1.08] | 0.217 |
Body mass index [kg/\({{\text{m}}}^{2}\)] | 1.04 [1.01, 1.06] | 0.001 | 0.99 [0.97, 1.02] | 0.622 |
Kreatinin [mg/dl] | 1.55 [1.16, 2.07] | 0.003 | 1.21 [0.88, 1.66] | 0.233 |
Bilirubin [mg/dl] | 1.33 [1.11, 1.59] | 0.002 | 1.33 [1.15, 1.54] | < 0.001 |
Restrictive lung disease [yes] | 1.02 [0.85, 1.21] | 0.853 | 1.17 [0.87, 1.57] | 0.311 |
Obstructive lung disease [yes] | 1.46 [1.22, 1.76] | < 0.001 | 1.43 [1.01, 2.02] | 0.041 |
FEV1 [% of reference] | 1.00 [0.99, 1.00] | 0.543 | 1.00 [0.99, 1.01] | 0.780 |
FVC [% of reference] | 1.00 [0.99, 1.00] | 0.769 | 0.99 [0.99, 1.00] | 0.042 |
Relevant CAD [yes] | 1.23 [0.92, 1.64] | 0.167 | 0.96 [0.71, 1.29] | 0.788 |
LVEF [abnormal] | 1.40 [0.97, 2.02] | 0.072 | 1.13 [0.82, 1.55] | 0.466 |
TAPSE [reduced] | 1.24 [0.88, 1.76] | 0.225 | 1.16 [0.85, 1.59] | 0.366 |
TI [\(>\)°II] | 1.33 [0.78, 2.27] | 0.291 | 1.44 [0.89, 2.35] | 0.141 |
mPAP [mmHg] | 1.00 [0.99, 1.01] | 0.751 | 1.01 [1.00, 1.02] | 0.108 |
PCWP [mmHg] | 1.03 [1.01, 1.05] | 0.004 | 1.01 [0.99, 1.03] | 0.248 |
Double Lung Transplant [yes] | 0.51 [0.43, 0.62] | < 0.001 | 0.65 [0.52, 0.80] | < 0.001 |
Reoperation [yes] | 2.91 [2.49, 3.39] | < 0.001 | 3.51 [2.97, 4.14] | < 0.001 |
ECMO [yes] | 0.75 [0.48, 1.18] | 0.215 | 0.94 [0.62, 1.42] | 0.758 |
Time since first transplantation at all in the study [years] | 0.98 [0.97, 1.00] | 0.068 | 0.97 [0.95, 0.99] | 0.001 |